AHSAN HABIB

Beximco Pharmaceuticals is approaching a critical deadline on the London Stock Exchange, with its securities facing a possible cancellation of admission to trading after nearly six months of suspension due to delayed financial reporting.

Trading of the company’s global depositary receipts (GDRs) on the Alternative Investment Market (AIM) of the London Stock Exchange has remained suspended since January 2.

The suspension followed Beximco Pharmaceuticals’ failure to publish its audited annual report and accounts for the financial year that ended on June 30, 2025, by the AIM deadline of December 31, 2025, along with subsequent financial disclosures.

Under Rule 19 of the AIM Rules for Companies, an AIM-listed issuer is required to publish its annual audited As Any

SEE PAGE 2 COL 4